Nkarta, Inc. – NASDAQ:NKTX

Add to watchlist

$2.34

-0.07

-2.9%

Market closed

Open in 3 days

-62.98%

month

-62.98%

quarter

-55.12%

year

Market Cap	162.66M
Enterprise value	228.56M

P/E	-1.52
EV/Sales	N/A
EV/EBITDA	-2.16
Price/Sales	N/A
Price/Book	0.49
PEG ratio	N/A
EPS	-2.35

Revenue	N/A
EBITDA	-124.75M
Income	-116.20M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Nkarta, Inc. (NASDAQ:NKTX): Profit margin
Jun 2023	0	-33.28M
Sep 2023	0	-25.64M
Dec 2023	10.54M	-27.75M	-263.27%
Mar 2024	0	-29.51M

Nkarta Financials Estimate

Q Y

Nkarta, Inc. (NASDAQ:NKTX): Analyst Estimates
Sep 2025	0	-27.81M
Oct 2025	0	-27.19M
Dec 2025	0	-34.34M
Dec 2025	0	-27.36M

Analysts Price target
Financials & Ratios estimates

Nkarta, Inc. (NASDAQ:NKTX): Debt to assets
Jun 2023	429038000	111.06M	25.89%
Sep 2023	405864000	109.04M	26.87%
Dec 2023	378885000	105.6M	27.87%
Mar 2024	576936000	103.28M	17.9%

Nkarta, Inc. (NASDAQ:NKTX): Cash Flow
Jun 2023	-21.77M	-3.17M	395K
Sep 2023	-20.27M	29.42M	0
Dec 2023	-23.35M	15.83M	295K
Mar 2024	-28.50M	21.48M	226.26M

Nkarta alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Nkarta, Inc. (NASDAQ:NKTX): Employee count
Aug 2023	165
Sep 2023	169
Oct 2023	169
Nov 2023	169
Dec 2023	167
Jan 2024	167
Feb 2024	167
Mar 2024	150
Apr 2024	150
May 2024	150
Jun 2024	150
Jul 2024	150

Nkarta
Hedge Funds Holdings Q1 2023

26.56% -59.90%

of NKTX is owned by hedge funds

55 -65

hedge funds hold NKTX stock

11.59M -30.45M

shares is hold by hedge funds

NKTX hedge funds holdings changes

Nkarta, Inc. (NASDAQ:NKTX): Insider trades (number of shares)
Period	Buy	Sel
Jun 2023	0	4030
Aug 2023	0	1331
Jan 2024	0	24875
Feb 2024	0	4143
Mar 2024	8000031	8367

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	27 Mar 2024	RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner: director, 10 percent owner:	Common Stock	3,000,000	$10	$30,000,000
Purchase	27 Mar 2024	RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner: director, 10 percent owner:	Pre- Funded Warrants (Right to Buy)	3,000,031	N/A	N/A
Purchase	27 Mar 2024	GEORGE SIMEON director director	Common Stock	1,548,341	$10	$15,483,410
Purchase	27 Mar 2024	GEORGE SIMEON director director	Common Stock	451,659	$10	$4,516,590
Option	1 Mar 2024	BRANDENBERGER RALPH officer: Chief Technical Officer officer: Chief Technical Officer	Common Stock	2,955	$3.89	$11,495
Option	1 Mar 2024	BRANDENBERGER RALPH officer: Chief Technical Officer officer: Chief Technical Officer	Common Stock	3,808	$3.89	$14,813
Sale	1 Mar 2024	BRANDENBERGER RALPH officer: Chief Technical Officer officer: Chief Technical Officer	Common Stock	8,367	$12.51	$104,671
Option	1 Mar 2024	BRANDENBERGER RALPH officer: Chief Technical Officer officer: Chief Technical Officer	Stock Option (right to buy)	2,955	$3.89	$11,495
Option	1 Mar 2024	BRANDENBERGER RALPH officer: Chief Technical Officer officer: Chief Technical Officer	Stock Option (right to buy)	3,808	$3.89	$14,813
Sale	12 Feb 2024	TRAGER JAMES officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	4,143	$12	$49,716

Status	Patent	Filling date	Issue date
Application	Application CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY Filling date: 7 Jan 2022 Issue date: 28 Jul 2022	7 Jan 2022	28 Jul 2022
Grant	Grant Utility: Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy Filling date: 27 Mar 2018 Issue date: 21 Jun 2022	27 Mar 2018	21 Jun 2022
Grant	Grant Utility: CD19-directed chimeric antigen receptors and uses thereof in immunotherapy Filling date: 4 Nov 2020 Issue date: 22 Feb 2022	4 Nov 2020	22 Feb 2022
Application	Application METHODS FOR THE SIMULTANEOUS EXPANSION OF MULTIPLE IMMUNE CELL TYPES, RELATED COMPOSITIONS AND USES OF SAME IN CANCER IMMUNOTHERAPY Filling date: 22 Nov 2019 Issue date: 17 Feb 2022	22 Nov 2019	17 Feb 2022
Application	Application GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY Filling date: 10 Jun 2021 Issue date: 6 Jan 2022	10 Jun 2021	6 Jan 2022
Application	Application NATURAL KILLER CELL COMPOSITIONS AND IMMUNOTHERAPY METHODS FOR TREATING TUMORS Filling date: 11 Sep 2019 Issue date: 4 Nov 2021	11 Sep 2019	4 Nov 2021
Grant	Grant Utility: Cancer immunotherapy using CD19-directed chimeric antigen receptors Filling date: 4 Nov 2020 Issue date: 26 Oct 2021	4 Nov 2020	26 Oct 2021
Grant	Grant Utility: Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy Filling date: 4 Nov 2020 Issue date: 12 Oct 2021	4 Nov 2020	12 Oct 2021
Application	Application IMMUNE CELLS ENGINEERED TO EXPRESS CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY Filling date: 4 Nov 2020 Issue date: 11 Mar 2021	4 Nov 2020	11 Mar 2021
Application	Application CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY Filling date: 4 Nov 2020 Issue date: 11 Mar 2021	4 Nov 2020	11 Mar 2021

Nkarta
Executives

Insider	Age	Compensation
Mr. Paul J. Hastings (1960) Chief Executive Officer, Pres & Director	65	$820,100
Dr. Nadir Mahmood Ph.D. (1979) Chief Financial & Bus. Officer	46	$479,180
Dr. Alicia J. Hager (1970) Chief Legal Officer & Corporation Sec.	55	$420,630

Nkarta
Latest News

Thursday, 5 December 2024
06:01	Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2	globenewswire.com
Tuesday, 26 November 2024
07:02	Nkarta to Participate in an Upcoming Investor Conference	globenewswire.com
Tuesday, 12 November 2024
08:02	Nkarta to Participate in an Upcoming Investor Conference	globenewswire.com
Thursday, 7 November 2024
16:02	Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights	globenewswire.com
Tuesday, 8 October 2024
09:07	Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month	benzinga.com
Tuesday, 3 September 2024
16:01	Nkarta to Participate in Upcoming Investor Conference	globenewswire.com
Wednesday, 14 August 2024
12:37	Why Nkarta Stock Is Soaring Today	fool.com
Tuesday, 13 August 2024
21:03	Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights	globenewswire.com
16:01	Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights	globenewswire.com
Tuesday, 16 July 2024
06:01	Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President	globenewswire.com
Wednesday, 10 July 2024
13:00	Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know	zacks.com
Monday, 1 July 2024
10:20	3 Undervalued Stocks Primed for a 2X Return	investorplace.com
Thursday, 27 June 2024
06:00	Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications	globenewswire.com
Thursday, 13 June 2024
16:01	Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors	globenewswire.com
Saturday, 25 May 2024
02:20	Nkarta: Finally An Attractive Valuation	seekingalpha.com
Thursday, 9 May 2024
16:01	Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights	globenewswire.com
Tuesday, 7 May 2024
06:30	Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's Radar	investorplace.com
Saturday, 27 April 2024
10:27	Nkarta: Down 50% Since March With A Clinical Catalyst Ahead	Seeking Alpha
Wednesday, 3 April 2024
16:02	Nkarta to Participate in Upcoming Investor Conferences	GlobeNewsWire
Sunday, 31 March 2024
08:55	Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO	24/7 Wall Street
Thursday, 29 February 2024
06:30	3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket	InvestorPlace
Wednesday, 28 February 2024
08:01	Nkarta to Participate in Upcoming Investor Conferences	GlobeNewsWire
Tuesday, 20 February 2024
16:19	Last Call! 7 Small-Cap Stocks Ready to Explode in Value	InvestorPlace
Thursday, 8 February 2024
09:32	3 Under-the-Radar Stocks Set to Soar 300% by 2026	InvestorPlace
Tuesday, 6 February 2024
12:50	3 Sleeper Stocks With Serious Potential to Make You a Millionaire	InvestorPlace
Monday, 5 February 2024
12:41	3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential	InvestorPlace
Sunday, 4 February 2024
08:00	Unseen Giants: 3 Stocks Quietly Preparing for a 10X Surge	InvestorPlace
Tuesday, 19 December 2023
10:11	Penny Stocks To Buy Now? 4 To Watch Before 2024	PennyStocks
Friday, 8 December 2023
13:32	All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy	Zacks Investment Research
Tuesday, 7 November 2023
08:02	Nkarta to Participate at Upcoming Investor Conferences	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 22 Jul 2025

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025
Seeking Alpha 25 May 2024

Nkarta: Finally An Attractive Valuation
Seeking Alpha 27 Apr 2024

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Seeking Alpha 25 Jan 2024

Nkarta: Possible Upside From H1 Update, If Positive
Seeking Alpha 12 Nov 2023

Fate Therapeutics: Getting There, But Perpetually
Seeking Alpha 26 Mar 2023

Nkarta: Going Down Despite Solid Data Due To Fate's Debacle
Seeking Alpha 2 Dec 2022

Nkarta: A Buy On Pullback With Valuation At Lows
Seeking Alpha 10 Nov 2022

Nkarta: Under The Radar Company With Brilliant Results
Seeking Alpha 23 Jun 2022

I-Mab Valuation Offers A Biotech Investment Opportunity
Seeking Alpha 20 May 2022

Nkarta: A Promising Natural Killer Cell Play

Frequently Asked Questions (FAQ)

What's the price of Nkarta stock today?

One share of Nkarta stock can currently be purchased for approximately $2.34.
When is Nkarta's next earnings date?

Unfortunately, Nkarta's (NKTX) next earnings date is currently unknown.
Does Nkarta pay dividends?

No, Nkarta does not pay dividends.
How much money does Nkarta make?

Nkarta has a market capitalization of 162.66M.
What is Nkarta's stock symbol?

Nkarta, Inc. is traded on the NASDAQ under the ticker symbol "NKTX".
What is Nkarta's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Nkarta?

Shares of Nkarta can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Nkarta's key executives?
Nkarta's management team includes the following people:
- Mr. Paul J. Hastings Chief Executive Officer, Pres & Director(age: 65, pay: $820,100)
- Dr. Nadir Mahmood Ph.D. Chief Financial & Bus. Officer(age: 46, pay: $479,180)
- Dr. Alicia J. Hager Chief Legal Officer & Corporation Sec.(age: 55, pay: $420,630)
How many employees does Nkarta have?

As Jul 2024, Nkarta employs 150 workers.
When Nkarta went public?

Nkarta, Inc. is publicly traded company for more then 5 years since IPO on 10 Jul 2020.
What is Nkarta's official website?

The official website for Nkarta is nkartatx.com.
Where are Nkarta's headquarters?

Nkarta is headquartered at 6000 Shoreline Court, South San Francisco, CA.
How can i contact Nkarta?

Nkarta's mailing address is 6000 Shoreline Court, South San Francisco, CA and company can be reached via phone at +41 55824923.

Nkarta, Inc.

nkartatx.com

Exchange:

NASDAQ

Full time employees:

159

Industry:

Biotechnology

Sector:

Healthcare

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

+41 55824923

6000 Shoreline Court
South San Francisco, CA 94080

CIK: 0001787400
ISIN: US65487U1088
CUSIP: 65487U108